Targeting granzyme B to tumor cells using a yoked human chorionic gonadotropin by Kanatani, Isao et al.
ORIGINAL ARTICLE
Targeting granzyme B to tumor cells using a yoked human
chorionic gonadotropin
Isao Kanatani • Xinjian Lin • Xiaoqin Yuan •
Gerald Manorek • Xiying Shang • Lawrence H. Cheung •
Michael G. Rosenblum • Stephen B. Howell
Received: 19 November 2010/Accepted: 26 January 2011/Published online: 16 February 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract
Purpose Luteinizing hormone receptor (LHR) is found in
abundance on human ovarian, breast, endometrial and
prostate carcinomas but at only low levels on non-gonadal
tissues. To selectively kill LHR-expressing tumors, gran-
zymeB(GrB)waslinkedtoaproteininwhichbothchainsof
human chorionic gonadotropin were yoked together (YCG).
Methods GrB-YCG was expressed and secreted from
insect Sf9 cells. Its GrB enzymatic activity and binding
afﬁnity for hLHR were then characterized. The differential
cytotoxicity of GrB-YCG versus GrB alone was tested in a
panel of LHR-expressing tumor cells by SRB assay, and
the mechanisms involved in the cell death were investi-
gated by confocal ﬂuorescence microscopy, ﬂow cytome-
try, and western blot analysis.
Results GrB-YCG was successfully expressed and
secreted from Sf9 insect cells and puriﬁed from cell culture
supernatants. The serine protease activity of GrB-YCG was
equivalent to that of human recombinant GrB. An in vitro
hormone binding assay revealed that the GrB-YCG
molecule also retained the ability to bind to the LHR
receptor with an afﬁnity similar to that of native hCG.
Upon cell binding, GrB-YCG was rapidly internalized into
LHR-expressing human ovarian cancer cells and produced
selective and potent tumor cell killing by inducing apop-
tosis through activation of caspase-3.
Conclusions These results validate LHR as a therapeutic
target and indicate that delivery of the human pro-apoptotic
enzyme GrB to tumor cells by yoked hCG has substantial
selectivity and therapeutic potential for human tumors that
express high levels of LHR such as ovarian carcinomas.
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Abbreviations
GrB Granzyme B
hCG Human chorionic gonadotropin
LHR Luteinizing hormone receptor
YCG Yoked human chorionic gonadotropin
rEK Recombinant enterokinase
Introduction
Ovarian cancer remains the most lethal gynecologic
malignancy in the United States. Although many patients
with advanced-stage disease initially respond to standard
combinations of surgical and cytotoxic therapy, nearly 90%
develop recurrence and inevitably die from the develop-
ment of resistance to cytotoxic chemotherapy [1]. There is
an urgent need to develop novel therapeutics that more
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mone receptor (abbreviated hLHR) is an attractive target
for this approach. This receptor speciﬁcally binds lutein-
izing hormone (LH) and human chorionic gonadotropin
(hCG) [2, 3], which normally have effects only on gonadal
tissues where they play an essential role in reproductive
function. While the hLHR is expressed at low levels on a
variety of other normal tissues [4–6], knockout of LHR in
mice does not affect the development of any tissues other
than reproductive organs [7]. hLHR is expressed at high
levels on ovarian [8–11], prostate [12], breast [13–15], and
endometrial [9, 16] cancers.
Granzyme B (GrB), a serine-dependent and aspartate-
speciﬁc protease, is the major effector molecule of cellular
immune defense and is released from the granules of
activated cytotoxic T lymphocytes or natural killer cells
during their attack on other cells. The mechanism by which
GrB is normally translocated into the cell is not fully
understood, although mannose-6-phosphate receptor-med-
iated endocytosis appears to play some part [17]. Once in
the target cell GrB is activated by the removal of two
amino acids at the N-terminus; the activated protein then
induces apoptosis through either caspase-dependent or
independent pathways [18]. Engineering the active form of
GrB into an immunotoxin not only conﬁnes the delivery of
the toxin to the antigen-expressing tumor cells, but also
eliminates the need for proteolytic activation once inter-
nalized into the target cell. Recently, we have demonstrated
that an immunotoxin consisting of GrB linked to a single-
chain antibody that targets the gp240 antigen (GrB/scFv-
MEL) was highly cytotoxic to melanoma cells in vitro and
was effective in producing a fourfold reduction in the
growth of human melanoma A375 xenografts [19]. Other
successful immunotoxins developed using human GrB
have included GrB/TGFa and GrB/anti-ErbB2 scFv that
selectively kill tumor cells expressing EGFR or ErbB2
[20], and GrB/VEGF121 that targets endothelial cells
involved in tumor angiogenesis [21].
Although several monoclonal antibodies to hLHR have
been reported [22, 23], there are currently no therapeutic
antibodies that are sufﬁciently speciﬁc to be used to direct
drugs to this target. However, extensive pre-clinical studies
have been completed using a peptide derived from the
b-chain of hCG to direct lytic peptides to breast and
prostate cancers that express hLHR (reviewed in [24, 25]).
The studies demonstrated that such fusion toxins could
produce responses in mice carrying human tumor xeno-
grafts, and one of these molecules was selected for further
development through the RAID program at the NCI. The in
vivo response to these toxins was reported to be directly
related to LHR density on the tumor cells [15, 25, 26]. Two
groups have made attempts to use hCG itself to target
either a membrane-disrupting lytic peptide [27]o r
ribosomal inactivating plant toxin gelonin [28] to this
receptor. However, because these molecules were immu-
nogenic, relatively impotent, and displayed very short half-
lives in the systemic circulation, neither molecule moved
forward into clinical development. Thus, we developed a
novel type of fusion toxin in which the a- and b-chains of
hCG are linked together to form a single protein (‘‘yoked’’
hCG, YCG) that is then fused to human granzyme B (GrB).
This protein molecule is designed to contain the tumor-tar-
geting moiety YCG that binds hLHR, and the toxin GrB that
is a potent apoptotic inducer capable of killing the hLHR-
overexpressing cancer cells. Here, we report that GrB-YCG
displayspotentandselectivecytotoxicitytowardtumorcells
expressing the target LH receptors.
Materials and methods
Reagents
Tissue culture media were purchased from Life Technolo-
gies (Frederick, MD) and Thermo Fischer Scientiﬁc (Wal-
tham, MA). Bac-to-Bac
 Baculovirus Expression system
with TOP10 and DH10Bac competent cells, and Sf9 insect
cell lines were purchased from Invitrogen (Carlsbad, USA).
The BacPak baculovirus titration kit was obtained from
Clontech (Mountain View, CA), and metal afﬁnity resin
Ni–NTA agarose from Qiagen (Valencia, CA). Rabbit anti-
His polyclonal antibody, mouse anti-human granzyme B
monoclonal antibody, and rabbit polyclonal anti-LHR anti-
body were purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA). Rabbit polyclonal antibody against
active ? pro Caspase 3 was purchased from Abcam, Inc.
(Cambridge, MA). Horseradish peroxisome (HRP) or Texas
red-labeled secondary antibodies against mouse or rabbit
immunoglobulin were obtained from Jackson Immuno-
Research Laboratories, Inc. (West Grove, PA). Human
recombinant granzyme B and N-a-t-butoxycarbonyl-L-ala-
nyl-L-alanyl-L-aspartyl-thiobenzyl ester (BAADT) were
purchased from Alexis Biochemicals (San Diego, CA) and
5-,50-dithiobis (2-nitro benzoic acid) (DTNB, Ellman’s
reagent) from Thermo Scientiﬁc. A native hCG was
purchased from Sigma–Aldrich (Saint Louis, MO), and
125I-hCG was obtained from PerkinElmer Life Sciences
(Boston, MA).
Cell lines and cell culture
The fall armyworm ovarian Sf9 cell line was maintained at
27C in HyClone SFX-INSECT medium supplemented
with 5% fetal bovine serum (FBS, Sigma–Aldrich,
St. Louis, MO), 100 U/ml penicillin, 100 mg/ml
980 Cancer Chemother Pharmacol (2011) 68:979–990
123streptomycin, and 25 lg/ml amphotericin B. The mouse
Leydig tumor cell line MA-10 expressing high levels of LH
receptor [29] was grown in RPMI 1640 (Gibco, Grand
Island, NY, USA) supplemented with 10% FBS,
4.5 g/l glucose, 2 mM L-glutamine, 100 U/ml penicillin,
100 mg/ml streptomycin, 10 mM HEPES (N-2-hydro-
xyethylpiperazine, N-2-ethanesulfonic acid), 2.2 M sodium
pyruvate, and 1.5 g/l sodium bicarbonate (all from Invit-
rogen, Carlsbad, CA), and cultures were maintained at
37C in a humidiﬁed atmosphere of 5% CO2 and 95% air.
The human ovarian carcinoma cell lines 2008 and CA-OV-
3 were grown in RPMI 1640 supplemented with 5% fetal
bovine serum.
Vector construction and virus preparation
A GrB-YCG fusion DNA construct was generated by an
overlapping PCR method. The human mature GrB gene was
ampliﬁed from the plasmid GrB-scFvMEL [30] by PCR
usingtheforwardprimerGrB-YCG-50(50-TCTTACATCT
ATG CCG ATC ACC ATC ATC ATC ATC ATG ACG
ACG ACG ACA AGA TCA TCG GGG GAC-30) and the
reverse primer GrB-YCG-4 (50-GGA GCC ACC GCC ACC
GTA GCG TTT CATGGT-30).Theresulting PCR fragment
was further extended at its 50 end in a second PCR using the
primers GrB-YCG-48 (50-C ACC ATG AAA TTC TTA
GTC AAC GTT GCC CTTGTT TTT ATG GTC GTA TAC
ATT TCT TAC ATC TAT GCC-30) and GrB-YCG-4. The
two-step PCR generated the fragment containing BamHI
restrictionsite,the30-aminoacidhoneybeemelittin(HBM)
secretionsignal,asix-histidinetag,andanenterokinase(EK)
cleavage site. The YCG gene was ampliﬁed from plasmid
yoked hCG-pVL1393 [31] by PCR using the primers GrB-
YCG-5(50-GGTGGCGGTGGCTCCTCCAAGGAGCC
GCT TCG-30) and GrB-YCG-51 (50-CT ATT AAG ATT
TGT GAT AAT AAC AAG TAC TGC-30). The fused GrB-
YCG genes were linked together by using primers GrB-
YCG-48andGrB-YCG-5.TheﬁnalGrB-YCGgeneproduct
from the splice overlap extension PCR (SOE-PCR) was
puriﬁed and cloned into the pFastBac1 vector at BamHI
and XhoI. The resulting plasmid pFastBac-GrB-YCG was
sequence-veriﬁed and used to prepare recombinant bacmids
by transposition in DH10Bac competent cells. Isolated
recombinant bacmid DNA was transfected into Sf9 cells to
produce the recombinant baculovirus coding for GrB-YCG
according to the manufacturer’s instructions for the Bac-to-
Bac Baculovirus Expression system (Invitrogen). The virus
was ampliﬁed to generate a stock with viral titers of greater
than 1 9 10
8 plaque-forming units/ml, as determined with
the BacPak baculovirus titration kit (Clontech), and used for
protein production.
Large-scale expression and puriﬁcation
of GrB-YCG fusion protein
Large-scale expression was performed using Sf9 cells
grown in 2.8 l plastic shaker ﬂasks (900 ml of culture per
ﬂask) in serum-free HyQ SFX-Insect medium at 27C and
shaking speed of 100 rpm. Cells were infected at an MOI
of 1 at a cell density of 1.0 9 10
6/ml. Cells were harvested
96 h after infection. All steps hereafter were performed at
4C except where otherwise noted. First, cells and cellular
debris were removed by centrifugation for 20 min at
3,000g. The supernatant was concentrated to one-thirtieth
of its initial volume by using Sartorius 10 kDa cut-off
Hydrosart Microﬁlter Cassette (Goettingen, Germany). The
concentrated medium that contained the soluble fraction of
the recombinant protein was loaded onto a Ni–NTA col-
umn. After washing the column 4 times with a wash buffer
(50 mM NaH2PO4, 300 mM NaCl, and 20 mM imidazole,
pH 8.0), the bound proteins were eluted with an elution
buffer containing 50 mM NaH2PO4, 300 mM NaCl, and
250 mM imidazole (pH 8.0). The buffer of the eluate was
exchanged by a PD-10 column (GE Healthcare, Piscata-
way, NJ) to 20 mM Tris–HCl (pH 7.4) and 50 mM NaCl.
The fusion protein was incubated with rEK (Novagen,
Madison, WI) to remove the 6xHis tag. rEK was removed
using EKapture Agarose according to manufacturer’s
instructions. The mixture without rEK was further applied
to a Ni–NTA column to remove incompletely digested
material, the cleaved N-terminal part of the protein con-
taining the 6xHis tag as well as other contaminating pro-
teins. The ﬁnal protein product was collected in the wash
buffer and buffer-exchanged with PBS using a PD-10
column.
Serine protease activity bioassay
The enzymatic activity of the GrB component was deter-
mined using a continuous colorimetric assay that utilized
N-a-t-butoxycarbonyl-L-alanyl-L-alanyl-L-aspartyl-thioben-
zyl ester (BAADT) as a speciﬁc substrate for the serine
protease activity of GrB [30]. Assays were performed in a
total volume of 100 ll and consisted of either recombinant
human GrB, GrB-YCG fusion protein before and after
cleavage by EK, or EK (control) in buffer A (0.2 M
HEPES, 0.2 M NaCl, 1 mM EDTA, 0.05% (v/v) Triton
X-100, pH 7.0), 0.3 mM 5,50-dithiobis-2-nitrobenzoic acid,
and 0.2 mM substrate BAADT at 25C. The change in
absorbance at A405nm was measured on a Versamax
microplate reader (Molecular Devices, Sunnyvale, CA).
Increases in sample absorbance were converted to enzy-
matic rates by using an extinction coefﬁcient of
13,100 cm
-1 M
-1 at 405 nm. The speciﬁc activity (SA) of
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Systems Products, Livermore, CA) as the standard.
Knockdown of LH receptor expression in Leydig cells
using shRNAi lentivirus MISSION
TM
Lentiviral Transduction Particles for knockdown of LHR
expression were purchased from Sigma (www.sigma-
aldrich.com/missionsearch). Brieﬂy, a culture containing
70–80% conﬂuent Leydig cells was transduced with shR-
NAi lentiviral constructs at various MOIs for 24 h. The
media containing lentiviral particles was then replaced with
fresh media, and after a subsequent 24 h successfully
transduced cells were selected by exposure to 10 lg/ml
puromycin. The puromycin-containing media was refre-
shed every 3–4 days until resistant colonies were identi-
ﬁed. A minimum of 5 puromycin-resistant clones was
picked and expanded into individual cell lines and assayed
for knockdown of LHR by a quantitative RT–PCR as
described below and by Western blot analysis.
Quantitation of LHR mRNA by real-time PCR
Total RNA was extracted with TRIzol
 reagent (Invitro-
gen). First-strand cDNA was synthesized using SuperScript
II reverse transcriptase (Invitrogen) and random primers.
Real-time PCR was done using the Bio-Rad iCycler iQ
detection system in the presence of SYBR Green I dye
(Bio-Rad Laboratories, Inc., Hercules, CA). For the LHR
gene expression, the forward (50-CGC TTT CCA AGG
GAT GAA TA-30) and reverse (50-CAT TGA ATG CAT
GGC TTT GT-30) primers were used for ampliﬁcation with
a iCycler protocol consisting of a denaturation program
(95C for 3 min), ampliﬁcation and quantiﬁcation program
repeated 40 times (95C for 10 s and 55C for 45 s), and
melting curve analysis. The data were analyzed by using
the comparative Ct method, where Ct is the cycle number
at which ﬂuorescence ﬁrst exceeds the threshold. The Ct
values from each cell line were obtained by subtracting the
values for b-actin Ct from the sample Ct. A 1-unit differ-
ence of Ct value represents a twofold difference in the level
of mRNA.
Analysis of binding of GrB-YCG to LHR
by competitive binding assay
The speciﬁcity of the binding of GrB-YCG to LHR was
determined using a competitive binding assay. Brieﬂy,
cells were plated at a density of 2.0 9 10
5 cells/well in
24-well plates and allowed to adhere overnight. The cells
were then exposed to 200 pM of
125I-hCG in Waymouth
medium containing 0.1% FBS in the presence of increasing
concentrations of unlabeled hCG or GrB-YCG for 6 h.
The ﬁnal total volume of the reaction mixture was 500 ll.
After washing with PBS 3 times, cells were lysed in 500 ll
of 1N NaOH and counted in a c-counter. An estimate of
nonspeciﬁc counts was determined in the presence of 1 lg/
ml hCG by adding 20 llo f2 5 lg/ml hCG stock into
480 ll cell culture containing 200 pM of
125I-hCG. The
speciﬁc binding after subtracting the nonspeciﬁc counts in
the absence of competitor was normalized to 100%.
The competition curves were plotted as a percentage of the
speciﬁc binding vs. increasing concentrations of hCG or
GrB-YCG on a log scale. The data were ﬁtted to a sig-
moidal equation to calculate IC50 values using the Prism
software (GraphPad Software, Inc., San Diego, CA).
Internalization and intracellular distribution of GrB
and GrB-YCG detected by immunoﬂuorescent staining
Cells were plated onto polylysine-coated 8-well chamber
slides at 10
5 cells/well and incubated at 37C overnight in
5% CO2 and air. Cells were treated with 50 nM GrB or
GrB-YCG at 37C for 1, 3 and 6 h and then washed with
glycine buffer (500 mM NaCl, 0.1 M glycine, pH 2.5) for
2 min to remove GrB-YCG from the cell surface, ﬁxed in
3.7% formaldehyde, permeabilized in PBS containing
0.2% Triton X-100 and washed with PBS. After nonspe-
ciﬁc binding was blocked with 1% BSA, cells were incu-
bated with primary antibodies at room temperature for 1 h
and then washed 3 times in PBS containing 0.1% Tween 20
for 10 min followed by staining with Texas red-coupled
secondary antibodies. After 3 ﬁnal washes with PBS con-
taining 0.1% Tween 20, cells were incubated with 0.1%
Hoechst 33342 for 15 min and mounted in DABCO
mounting medium. Microscopic imaging was performed at
the University of California San Diego Cancer Center
Digital Imaging Shared Resource using a Zeiss LSM510
confocal microscope system (Carl Zeiss, Inc. Thornwood,
NY). Images were captured from 0.8-lm sections with a
639 lens and analyzed by SoftWorx software (Applied
Precision, Inc).
In vitro cytotoxicity of GrB versus GrB-YCG
The cells to be tested were plated into 96-well plates at a
density of 2,000 cells/well and allowed to adhere overnight
and then exposed to different concentrations of either
recombinant GrB or puriﬁed GrB-YCG. The effects of GrB
and GrB-YCG on the growth of tumor cells in culture were
determined by SRB assay as described previously [32].
Brieﬂy, cells were allowed to grow for 96 h in the presence
of drugs, after which the media were removed, and the
protein was precipitated with 50% trichloroacetic acid and
stained using 100 ll of 0.4% sulforhodamine B in 1%
acetic acid at room temperature for 15 min. After washing,
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recorded using a Versamax microplate reader (Molecular
Devices, Sunnyvale, CA). To examine the protective effect
of hCG on GrB-YCG cytotoxicity, the MA-10 cells were
treated with the indicated concentrations of hCG for 1 h,
washed twice, and challenged with 250 nM GrB-YCG for
96 h. Cell viability was determined by the SRB assay as
described above. All experiments were repeated at least 3
times using 3 cultures for each drug concentration.
Flow cytometric analysis of cell death
and caspase-3 cleavage assay
For determining phase distribution of DNA content within
the cells treated with 50 nM GrB-YCG for 24, 48, and
72 h, propidium iodide (PI) staining was performed.
Brieﬂy, 2 9 10
6 cells collected were washed once and
ﬁxed in 70% ethanol for 24 h. After centrifugation at
400gfor10 minat4C,cellpelletwasstainedwith50 lg/ml
PI (Sigma, St. Louis, MO) plus 0.5 mg/ml RNaseA in PBS
buffer for 15 min at room temperature in the dark. Analysis
was performed with FACScan ﬂow cytometer (Becton–
Dickinson, Mansﬁeld, MA). The analysis of cell percent-
age in the sub-G1 phase of cell cycle was performed using
the CellQuest software. For detection of caspase-3 cleav-
age, the cells were exposed to 50 nM GrB-YCG for various
times (0, 24 and 48 h), and the cell lysate was analyzed by
4–15% SDS–PAGE and immunoblotting using a rabbit
polyclonal anti-caspase-3 antibody (Abcam, Cambridge,
MA) recognizing both a proform and active/cleaved forms
of caspase-3.
Results
Expression, puriﬁcation, and identiﬁcation
of GrB-YCG fusion protein
We constructed a hormonotoxin in which GrB was fused at
its C-terminal end via a ﬂexible linker to YCG (Fig. 1a).
This protein was secreted into the culture medium via
the honey bee melittin signal sequence and puriﬁed by
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Fig. 1 a Schematic of the structure of hexahistidine-tagged GrB-
YCG. b Commassie blue-stained SDS–PAGE gel run under reducing
conditions showing steps in GrB-YCG puriﬁcation. The gel shows
analysis of medium from infected Sf9 cells, and the subsequent steps
in puriﬁcation. Lane 1 protein markers; lane 2 medium from infected
Sf9 cells; lane 3 ultraﬁltrate from 10 kDa cut-off Hydrosart Micro-
ﬁlter Cassette when concentrating the harvested medium; lane 4
concentrated medium; lane 5 6xHis-tagged GrB-YCG after puriﬁca-
tion by nickel-NTA metal afﬁnity chromatography; lane 6 rEK-
cleaved mixture; lane 7 ﬁnal puriﬁed GrB-YCG. c Western blot
analysis of the puriﬁed GrB-YCG fusion protein before and after rEK
cleavage. d Enzymatic activity of GrB-YCG. The GrB-YCG
displayed intact serine protease activity at the same level as human
recombinant GrB only after the cleavage by rEK
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123nickel-NTA immobilized metal afﬁnity chromatography
(IMAC) to 80–90% purity as assessed by SDS–PAGE
(Fig. 1b). Yields were found to be 1–2 mg of puriﬁed
protein per liter of culture. The protein migrated with an
apparent molecular mass signiﬁcantly higher than the
53.3 kDa calculated from the amino acid sequence. This
was likely due to glycosylation that occurred when the
protein was produced in Sf9 cells. The hexahistidine tag
was removed by cleavage with recombinant enterokinase
(rEK) resulting in the ﬁnal GrB-YCG product with no other
contaminating bands as shown in Lane 7 of Fig. 1b. The
identity of the cleaved fusion protein was conﬁrmed by
Western blot analysis of the uncleaved and rEK-cleaved
protein using anti-his, anti-GrB, and anti-hCG antibodies.
As shown in Fig. 1c the cleaved protein was detected by
both anti-GrB and anti-hCG antibodies but not by anti-his
antibody indicating that the hexahistidine tag had been
successfully removed. To assess the biological activity of
the GrB component of the fusion construct, the ability of
the enzyme to cleave a BAADT substrate was assessed and
compared with the activity of native recombinant GrB.
Figure 1d showed that neither rEK nor GrB-YCG con-
taining the hexahistidine tag were able to hydrolyze the
BAADT substrate, whereas removal of the hexahistidine
tag resulted in activity comparable to that of recombinant
native GrB.
Generation and characterization of LHR knockdown
cells
To establish a biological system for testing the potency and
selectivity of the GrB-YCG toxin, we performed a shR-
NAi-mediated constitutive knockdown of LHR expression
in the transformed murine Leydig cell line MA-10 using
shRNAi lentivirus. LHR-positive MA-10 cells were
infected with mouse LHR shRNAi-expressing lentivirus.
Individual puromycin-resistant clones were expanded, and
the resulting populations were screened for LHR mRNA
expression by RT–PCR. The population with the greatest
percent reduction in LHR was designated MA10-LHRKD-
5.3. As shown in Fig. 2a, the LHR mRNA levels in the
clone MA10-LHRKD-5.3 were reduced to 10.9% of that in
the parental MA-10 cells. The decreased expression of
mLHR mRNA was accompanied by a 93% reduction in
the capacity of the cells to bind
125I-hCG (Fig. 2b). LHR
receptor number was determined by a competitive binding
assay as reported previously [33] in which the hCG was
used as both radioligand and competitor. This revealed that
the MA10-LHRKD-5.3 cells expressed only 3.85 9 10
4
LHR/cell, whereas there were *1.22 9 10
6 LHR/cell on
the parental MA-10 cells; a 97% reduction in LHR levels
on the cell surface.
Binding of GrB-YCG to LHR on tumor cells
The ability of YCG component of GrB-YCG to bind to the
LHR was determined by competitive binding assay. MA-
10 cells were incubated with
125I-hCG and increasing
concentrations of native hCG or GrB-YCG. The displace-
ment curves (Fig. 3) indicate that the afﬁnities of the
standard urinary hCG and GrB-YCG for the LH receptor
were only twofold different with IC50 values of 70.6 and
132.4 nM, respectively.
Internalization of GrB-YCG into LHR-expressing
tumor cells
The ability of YCG to cause the internalization of the
linked GrB component was assessed by exposing the
parental MA-10 and the LHR-knockdown MA10-
LHRKD-5.3 cells to 50 nM of either recombinant GrB
or GrB-YCG for 3 h and determining the amount of
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Fig. 2 Generation and
characterization of clones of
Leydig tumor cells in which
LHR expression had been
knocked down. a Relative LHR
mRNA levels in the parental
MA-10 and MA10-LHRKD-5.3
subline. b Relative binding of
125I-hCG to LHR on the MA-10
and MA10-LHRKD-5.3 cells
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123intracellular GrB using an antibody speciﬁc for GrB and
quantitative analysis of confocal images. As shown in
Fig. 4, we found no signiﬁcant GrB staining following
exposure of either type of cell to recombinant GrB.
However, GrB-YCG was shown to be extensively inter-
nalized into the parental MA-10 cells (Fig. 4c). This
internalization was eliminated by the knockdown of LHR
because minimal staining was observed in the MA10-
LHRKD-5.3 cells. In the majority of the treated MA-10
cells, both diffuse and patchy staining was found within
the cytoplasm suggesting efﬁcient uptake of GrB-YCG
into endosomes and its subsequent release into the
cytoplasm. Signiﬁcant levels of cytosolic GrB-YCG were
also found in 2008 and OVCAR-3 ovarian carcinoma
cells treated with 250 nM GrB-YCG for 3 h (data not
shown). These results indicate that binding of the YCG
component of the GrB-YCG to LHR on the tumor cell
surface is responsible for its internalization.
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Fig. 3 Competitive binding assay with GrB-YCG. Leydig tumor
cells were treated with 200 pM of
125I-hCG and increasing concen-
trations of native hCG (ﬁlled square) or GrB-YCG (ﬁlled triangle) for
6 h. The speciﬁc binding of
125I-hCG in the absence of competitor is
normalized to 100%. Each data point represents the mean ± SEM of
3 independent experiments
Fig. 4 Internalization of GrB-YCG into the parental MA-10 and
MA10-LHRKD-5.3 cells treated with 50 nM GrB-YCG for 3 h. Cells
were permeabilized and stained with mouse anti-GrB and Texas
red-conjugated anti-mouse IgG, while nuclei were stained with
Hoechst 33342. a Untreated parental MA-10 cells; b MA-10 cells
exposed to recombinant GrB; c MA-10 cells exposed to GrB-YCG;
d untreated MA10-LHRKD-5.3 cells; e MA10-LHRKD-5.3 cells
exposed to GrB; f MA10-LHRKD-5.3 cells exposed to GrB-YCG
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123In vitro cytotoxic effects of GrB-YCG
To examine the potency and selectivity of GrB-YCG, we
compared the cytotoxicity of free GrB and GrB-YCG to
the MA-10, 2008 and OVCAR-3 cells. Figure 5a shows
that whereas free GrB produced no killing of the LHR-
expressing MA-10 cells up to a concentration of 1 lM,
GrB-YCG produced a concentration-dependent reduction
in viability with an IC50 of 0.16 lM. In contrast, GrB-YCG
was not cytotoxic to MA10-LHRKD-5.3 cells at concen-
tration of up to 1 lM (Fig. 1, supplementary material), a
concentration that killed 99.9% of the MA-10 cells. Similar
results were obtained with the ovarian cancer cell lines
2008 and OVCAR-3. At the highest concentration tested
(1 lM), GrB-YCG produced 90% inhibition of cell growth
in the both cell lines, whereas native GrB caused only 35
and 9% growth inhibition of the LHR-expressing OVCAR-
3 (Fig. 5b) and 2008 (Fig. 5c) cells, respectively. Inter-
estingly but expectedly, the recombinant fusion construct
GrB-YCG also demonstrated a differential cytotoxicity
against LHR-expressing human breast cancer cell line
MCF-7 and human prostate cancer cell line PC-3, com-
pared to GrB alone (Fig. 2, supplementary material). To
further conﬁrm that the enhanced cytotoxicity of GrB-YCG
was dependent on the YCG moiety, MA-10 cells were pre-
treated with increasing concentrations of free hCG and then
exposed to a cytotoxic concentration of GrB-YCG. As
shown in Fig. 5d, hCG protected the MA-10 cells in a
concentration-dependent manner when they were subse-
quently challenged with 0.25 lM GrB-YCG. These results
are consistent with the concept that pre-incubation with
hCG protected MA-10 cells by saturating the LH receptors
that mediate the cytotoxicity of GrB-YCG.
GrB-YCG-induced apoptosis and caspase-3 cleavage
Changes in DNA integrity are the hallmark of cellular
apoptosis. The occurrence of apoptotic cell death was
(a) (b)
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Fig. 5 Cytotoxic effect of
GrB-YCG on the LHR-
expressing MA-10 (a),
OVCAR-3 (b) and 2008
(c) cells and the protective
effect of hCG on the
cytotoxicity of GrB-YCG in the
MA-10 cells (d). (ﬁlled square)
GrB; (ﬁlled triangle) GrB-YCG.
Each data point represents the
mean of 3 independent
experiments each performed
with triplicate cultures. Vertical
bars, ±SEM
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123analyzed by ﬂow cytometry after staining of cells with
prodium iodide; the fraction of dead cells is represented by
the sub-G1 ﬂuorescent peak. As shown in Fig. 6a, 24 h
after treatment with 50 nM GrB-YCG, the LHR-expressing
MA-10 cells started to show an increase in the percentage
of apoptotic cells. The apoptotic fraction of the treated cells
increased to 25.3 and 54.8% at 48 h and 72 h, respectively.
The majority of apoptosis induced by GrB is known to be
mediated by caspase-3 activation, so we next examined the
effects of GrB-YCG on the activation of caspase-3. After
treatment of the MA-10 cells with the fusion construct for
24 or 48 h, procaspase-3 was shown to be cleaved into the
large (17 kDa) and small (12 kDa) subunits of active/
cleaved caspase-3 (Fig. 6b).
Discussion
Epithelial tumors of the ovary are highly lethal, but at least
40% of these tumors express the luteinizing hormone
receptor (LHR) at high levels, as do many prostate and
breast cancers [34]. Therefore, the LH receptor is of
interest with respect to the selective delivery of cytotoxic
agents directly into these malignant cells. While efforts
have been made to use a 15-amino acid segment of the beta
chain of hCG to target a membrane-disrupting lytic peptide
[27] or to use full-length hCG itself to target a ribosomal
inactivating plant toxin gelonin [28] to this receptor, these
molecules were potentially immunogenic, relatively
impotent and have very short half-lives in the systemic
Fig. 6 Apoptosis induction
by GrB-YCG in the
LHR-expressing MA-10 cells.
a Quantiﬁcation of sub-G1 peak
by ﬂow cytometry.
M1 percentage of apoptotic cells
and debris (damaged cells) in
the sub-G0 fraction,
R3 represents the apoptotic
nuclei with reduced DNA
content excluding the debris.
b GrB-YCG-induced caspase-3
cleavage in the MA-10 cells
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123circulation. In addition, these molecules are chemical
conjugates. On the one hand, premature release of cyto-
toxic agents from such conjugates due to linker degradation
can result in nonspeciﬁc toxicity; on the other hand, linkers
that are too stable can result in failure to release the active
agent in a timely manner, thereby compromising the
effectiveness of the successfully delivered agent [35]. Two
developments support the approach of directly fusing a
toxin to hCG rather than utilizing chemical conjugation.
First, it has now been shown that the b- and a-chains of
hCG can be connected by a short linker and produced as a
single polypeptide chain (‘‘yoked hCG’’) that retains high
afﬁnity and speciﬁcity for the LHR [31]. Second, human
GrB has been validated as a highly effective toxin that,
when introduced into the interior of the cell through link-
age to a targeting moiety, rapidly triggers apoptosis [30].
Such fusion toxins have already been shown to have
attractive pharmacokinetic characteristics and to have
efﬁcacy in a variety of different tumor models [21, 36].
A single protein containing GrB fused to a targeting moiety
is more attractive as a therapeutic than a molecule to which
a toxin has been chemically conjugated due to the fact that
the former approach eliminates concern about the linker
and results in a molecule that is likely less immunogenic
and thus compatible with multiple cycles of administration.
We have successfully expressed the GrB-YCG fusion
toxin, consisting of the human pro-apoptotic serine protease
GrB and the b- and a-chains of hCG yoked together, as
secreted protein in insect Sf9 cells with the yields of
approximately 1.5 mg per liter of culture medium. This
protein was designed to contain a hexahistidine tag and
enterokinasecleavagesiteattheN-terminalendsuchthatthe
fusion protein could be easily puriﬁed by afﬁnity chroma-
tography and active GrB could be released by cleavage with
enterokinase.TherEK-cleavedﬁnalproductwasrecognized
by both anti-GrB and anti-hCG antibodies but not by anti-
body to the hexahistidine tag consistent with the removal of
the N-terminal tag. The GrB-YCG containing the histidine
tag, or from which it had been removed, were then tested for
their ability to cleave an artiﬁcial peptide substrate Boc-
AlaAlaAsp-thiobenzyl ester. Theproteinfrom which the tag
had been removed, but not that containing the tag, cleaved
the synthetic GrB substrate, and its activity was indistin-
guishable from that of native GrB. The ﬁnal fusion protein
GrB-YCG was bifunctional in that it contained GrB activity
and was also capable of binding speciﬁcally to MA-10 cells
expressing high levels of the LHR receptor. The afﬁnity of
the GrB-YCG for LHR was only twofold lower than that
of native urinary hCG (IC50 132.4 nM vs. 70.6 nM),
presumably due to differences in glycosylation between
the recombinant and native hCG. It is known that baculovi-
rus-expressed glycoprotein does not contain sialic acid
becauseSf9 cells, while having a glycosylation apparatus
capable of synthesizing high mannose type carbohydrates
and simple O-linked chains [37], lack sialytransferases
[31].
Wild-type GrB is able to internalize slowly into target
cells, but localizes in vesicular structures inside the cyto-
plasm where it remains inactive [38]. Induction of apoptosis
is only observed after the addition of perforin which is
thought to liberate GrB from these vesicles, allowing assess
of the protease to the cytosol. Recent studies have suggested
that the mannose-6-phosphate receptor [17] could also
mediate GrB entry by receptor-mediated endocytosis [38]
and that under these circumstances perforin may act to
releaseendosomalGrBintothecytosolofthetargetcell[39].
The current study clearly demonstrates that the yoked hCG
can mediate the selective cellular accumulation of GrB in
cells expressing the LHR. Based on the fact that such uptake
isaccompaniedbycellularcytotoxicity,somefraction ofthe
GrBmustgainaccesstothecytoplasmevenintheabsenceof
perforin. Although nonspeciﬁc cellular entry of GrB could
possibly be mediated by the mannose-6-phosphate receptor,
the substantially enhanced cytotoxicity of GrB-YCG com-
pared to unmodiﬁed GrB indicated that YCG is the carrier
moleculethatdeliverstheattachedGrBintothecytoplasmof
target tumor cells after binding to the cell surface LHR.
Consistent with this ﬁnding, immunoﬂuorescent staining
clearly showed that GrB-YCG was found in much greater
abundance than GrB alone in LHR-positive MA-10 cells
following a 3-h exposure to equal concentrations, and that
GrBstainingwasminimalinLHR-knockdowncellsexposed
to either GrB-YCG or GrB only.
An ideal carrier would be a nonimmunogenic molecule
bindingtoacellsurfacereceptorexpressedpredominantlyin
cancer cells. Furthermore, after binding to the cell surface,
the fusion toxin should be transferred into the cytoplasm.
hCG fulﬁlls most of these criteria since it is nonimmuno-
genic, has a long plasma half-life, binds avidly to a cell
surface LHR, and is transferred into the cell after binding.
hCG receptors are expressed at high levels in tissues of the
female genital tract, and its malignancies but not in most
other tissues. The function of hCG and hCG receptors in
gynecologic malignancies isstill somewhat unclear.Kuroda
et al. [40] studied the biological aspect of LH/hCG action in
ovarian cancer using the LH/hCG receptor-positive OV-
CAR-3 and LHR-negative SK-OV-3 cell lines and showed
that treatment with hCG did not affect cell proliferation in
either cell line, consistent with our ﬁnding that hCG alone
evenat12.5 lMdidnotaffecttheviabilityofMA-10cells.It
is reasonable to speculate that the increased cytotoxic
activity of GrB-YCG is attributable to speciﬁc uptake of the
molecule due to YCG binding to the LHR not to any addi-
tionaltoxiceffectofYCGitself.Furthermore,treatmentwith
a mixture of hCG and GrB that had not been fused together
did not show any enhancement of cell killing over that
988 Cancer Chemother Pharmacol (2011) 68:979–990
123produced by GrB on LHR-positive cell lines (Fig. 3, sup-
plementary material).
Our data demonstrate that GrB-YCG can be readily
expressed in Sf9 cells and that, upon speciﬁc binding to the
LHR on the surface of tumor cells, the fusion molecules are
internalized and distributed into the cytosol resulting in
efﬁcient cell killing. Since both the GrB and yoked hCG
components of GrB-YCG are of human origin, the risk that
the molecule will be immunogenic is substantially reduced.
Toxins such as gelonin, Pseudomonas exotoxin, or ricin
toxin A chain, which are derived from plants or bacteria, are
highlyimmunogenicinhumans[41]andtendtoinducedrug
resistance after several treatments [42]. Because GrB acti-
vates numerous independent cascade events through enzy-
matic mechanisms of action, the development of resistance
toGrBisunlikely.GrB-YCGhaspotentialastheﬁrstofnew
class of cancer chemotherapeutic agents for the treatment of
ovarian, breast, and prostate carcinomas, as well as other
types of tumors that express high levels of the LH receptor.
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